Key result
AMI hospitalizations during interventional cardiology meetings link to ~8% lower 30-day mortality vs nonmeeting dates.
Why the study?
Previous research found lower 30-day mortality for acute cardiovascular patients treated in teaching hospitals during national cardiology meetings, but data specific to acute myocardial infarction were limited.
Does hospitalization during national interventional cardiology meetings reduce 30-day mortality in Medicare beneficiaries with acute myocardial infarction?
Observational (n=34,709)
Yes
Does hospitalization during national interventional cardiology meetings reduce 30-day mortality in Medicare beneficiaries with acute myocardial infarction?
Hospitalization for acute myocardial infarction during national interventional cardiology meetings is associated with lower 30-day mortality, particularly among medically managed NSTEMI patients.
Background Previous research has found that patients with acute cardiovascular conditions treated in teaching hospitals have lower 30‐day mortality during dates of national cardiology meetings. Methods and Results We analyzed 30‐day mortality among Medicare beneficiaries hospitalized with acute myocardial infarction (overall, ST‐segment–elevation myocardial infarction, and non–ST‐segment–elevation myocardial infarction) from January 1, 2007, to November 31, 2012, in major teaching hospitals during dates of a major annual interventional cardiology meeting (Transcatheter Cardiovascular Therapeutics) compared with identical nonmeeting days in the ±5 weeks. Treatment differences were assessed. We used a database of US physicians to compare interventional cardiologists who practiced and did not practice during meeting dates (“stayers” and “attendees,” respectively) in terms of demographic characteristics and clinical and research productivity. Unadjusted and adjusted 30‐day mortality rates were lower among patients admitted during meeting versus nonmeeting dates (unadjusted, 15.3% [482/3153] versus 16.7% [5208/31 556] [ P =0.04]; adjusted, 15.4% versus 16.7%; difference −1.3% [95% confidence interval, −2.7% to −0.1%] [ P =0.05]). Rates of interventional cardiologist involvement were similar between dates (59.5% versus 59.8% of hospitalizations; P =0.88), as were percutaneous coronary intervention rates (30.2% versus 29.1%; P =0.20). Mortality reductions were largest among patients with non–ST‐segment–elevation myocardial infarction not receiving percutaneous coronary intervention (16.9% versus 19.5% adjusted 30‐day mortality; P =0.008). Compared with stayers, attendees were of similar age and sex, but had greater publications (18.9 versus 6.3; P <0.001), probability of National Institutes of Health funding (5.3% versus 0.4%; P <0.001), and clinical trial leadership (10.3% versus 3.9%; P <0.001), and they performed more percutaneous coronary interventions annually (85.6 versus 63.3; P <0.001). Conclusions Hospitalization with acute myocardial infarction during Transcatheter Cardiovascular Therapeutics meeting dates was associated with lower 30‐day mortality, predominantly among patients with non–ST‐segment–elevation myocardial infarction who were medically managed.
No takes yet. Share an insight, caveat, or question.
Jena et al. (2018) conducted an observational in Acute myocardial infarction (n=34,709). Hospitalization during dates of a major annual interventional cardiology meeting vs. Identical nonmeeting days in the ±5 weeks was evaluated on 30-day mortality (difference -1.3%, 95% CI -2.7% to -0.1%, p=0.05). Hospitalization for acute myocardial infarction during interventional cardiology meetings was associated with lower adjusted 30-day mortality than on nonmeeting dates (15.4% vs 16.7%; P=0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: